Last reviewed · How we verify
Radiotherapy and PCV chemotherapy
This combination uses ionizing radiation to destroy tumor cells directly while chemotherapy with procarbazine, lomustine, and vincristine (PCV) enhances cell death through DNA damage and mitotic inhibition.
This combination uses ionizing radiation to destroy tumor cells directly while chemotherapy with procarbazine, lomustine, and vincristine (PCV) enhances cell death through DNA damage and mitotic inhibition. Used for Glioblastoma or high-grade glioma (Phase 3 trial context).
At a glance
| Generic name | Radiotherapy and PCV chemotherapy |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Combination chemotherapy and radiation therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Radiotherapy delivers high-energy radiation to tumor sites, causing direct DNA damage and cell death. PCV chemotherapy is a multi-agent regimen where procarbazine and lomustine are alkylating agents that cross-link DNA, and vincristine is a vinca alkaloid that disrupts microtubule formation. Together, these modalities work synergistically to maximize tumor cell killing while attempting to preserve normal tissue.
Approved indications
- Glioblastoma or high-grade glioma (Phase 3 trial context)
Common side effects
- Myelosuppression (anemia, thrombocytopenia, leukopenia)
- Nausea and vomiting
- Fatigue
- Radiation dermatitis
- Peripheral neuropathy
- Secondary malignancy
Key clinical trials
- A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (PHASE3)
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (PHASE3)
- gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas (PHASE3)
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (PHASE3)
- Triple Negative Breast Cancer and Celecoxib. Pilot Study (PHASE2)
- Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma (PHASE2, PHASE3)
- Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas (EARLY_PHASE1)
- Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiotherapy and PCV chemotherapy CI brief — competitive landscape report
- Radiotherapy and PCV chemotherapy updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI